News
Roche’s Multiple Sclerosis Drug Candidate Fenebrutinib Meets Main Goal in Late-Stage Trial
Swiss drugmaker Roche announced that its experimental multiple sclerosis treatment, Fenebrutinib, achieved its primary goal in a late-stage clinical trial by significantly reducing annual relapse rates compared to Aubagio (teriflunomide) over a 96-week treatment period.
Basel, November 11 —
Swiss pharmaceutical giant Roche (ROG.S) said on Monday that its experimental multiple sclerosis (MS) drug Fenebrutinib met its primary endpoint in a late-stage clinical trial for patients with relapsing forms of the disease.
In a company statement, Roche reported that over a 96-week treatment period, Fenebrutinib significantly reduced the annual relapse rate compared with teriflunomide (marketed as Aubagio), the current standard therapy for MS.
The company said detailed results will be presented at an upcoming medical conference and shared with regulatory authorities worldwide.
